Would you use encorafenib with cetuximab vs encorafenib alone as second line therapy in a patient with metastatic colon cancer with concomitant KRAS G12V and BRAF V600E mutations identified on liquid biopsy?

Topics: Gastrointestinal Cancers • Medical Oncology • Colorectal Cancer

Of note - the tumor tissue biopsy NGS did not show KRAS or BRAF mutations. Microsatellite stable. Patient received first line FOLFOXIRI + Avastin .

Answer from: Medical Oncologist at Academic Institution

This case represents two questions. First one has to do with the accuracy of KRAS and BRAF detected in liquid biopsy and not on the tissue specimen, and second one has to do with the use of encorafenib/cetuximab for this presumed BRAF and KRAS mutated case.Liquid biopsies are very accurate in detect...

Comments

Medical Oncologist at Rutgers Cancer Institute of New Jersey
This almost never occurs and most likely represent...

Answer from: Medical Oncologist at Community Practice

I would rather state this question as, "Would you use encorafenib with cetuximab or cetuximab with encorafenib plus binimetinib (triplet regimen), or cetuximab in combination with irinotecan based chemotherapy?"Based on the available data, it seems like KRAS mutation was not relevant. BEACON trial (...

Related Questions